RA
55 programs · 52 companies
Programs
55
Companies
52
Trials
57
MOAs
35
IL-13iPI3KiKRASG12CiBTKiTNFiSGLT2iAuroraAiMALT1iHER2EGFRi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7975 | Phase 3 | FXIa | ||
| NVS-5126 | Phase 3 | SHP2 | ||
| Pexazasiran | Preclinical | FXIa | ||
| Zanumavacamten | Phase 2/3 | TROP-2 | ||
| Talalemzoparlimab | Phase 1 | FcRn | ||
| MRN-8225 | Preclinical | TNFα | ||
| MRN-5715 | NDA/BLA | CDK4/6 | ||
| Gelisertib | Approved | IL-23 | ||
| RCU-2903 | NDA/BLA | EGFR | ||
| IRO-8712 | Preclinical | JAK2 | ||
| Tirasacituzumab | NDA/BLA | PI3Kα | ||
| Mavuvorutinib | Phase 1/2 | CD47 | ||
| Polasotorasib | NDA/BLA | FXIa | ||
| ARX-3681 | Phase 2 | PD-1 | ||
| DAN-IIT-673 | Preclinical | Menin | ||
| MAY-IIT-825 | Approved | GLP-1R | ||
| SEO-IIT-678 | Phase 2 | KIF18A | ||
| CER-4594 | Phase 3 | TROP-2 | ||
| Nidanesiran | Approved | CDK4/6 | ||
| Rilunaritide | Phase 1 | ALK | ||
| CGE-9788 | Phase 3 | APOC3 | ||
| Tirazanubrutinib | Phase 1 | ALK | ||
| Rimazasiran | Approved | BCL-2 | ||
| Datoderotide | Phase 3 | LAG-3 | ||
| 993-1656 | Preclinical | TIM-3 | ||
| Zanutapinarof | Approved | HER2 | ||
| Mavusotorasib | Phase 1/2 | B7-H3 | ||
| GLO-9656 | NDA/BLA | GPRC5D | ||
| Zenoosocimab | Phase 1 | TNFα | ||
| CAR-9528 | Preclinical | SOS1 | ||
| AJA-7840 | NDA/BLA | GPRC5D | ||
| INT-430 | Phase 2/3 | CD19 | ||
| CLS-4466 | NDA/BLA | CD20 | ||
| Lisofotisoran | Approved | TNFα | ||
| Nirarapivir | Phase 2 | FGFR | ||
| Polalemzoparlimab | Phase 2/3 | MDM2 | ||
| SPA-2229 | Phase 1 | KIF18A | ||
| DIC-4437 | Approved | PD-L1 | ||
| Cevirasimod | Phase 2/3 | IL-17A | ||
| 418-7316 | Phase 2/3 | KRASG12C | ||
| 003-1437 | Phase 2 | CGRP | ||
| Lisonaritide | Preclinical | CD20 | ||
| Ivozumab | Phase 1 | RET | ||
| Zenotuximab | Phase 2/3 | FGFR | ||
| MAG-3823 | Phase 1 | WEE1 | ||
| 416-6807 | Phase 2 | CD3 | ||
| CHA-IIT-602 | NDA/BLA | WEE1 | ||
| PET-IIT-588 | Phase 2 | CD20 | ||
| FUD-IIT-103 | Preclinical | TIM-3 | ||
| KIN-IIT-763 | Phase 1/2 | JAK1 | ||
| Gozefutibatinib | NDA/BLA | WRN | ||
| Nidaratamab | Approved | C5 | ||
| Fixazasiran | Phase 2/3 | PD-L1 | ||
| Pexalucimab | Phase 3 | EZH2 | ||
| PAT-6991 | Phase 1/2 | CDK2 |
Trials (57)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT04271069 | NVS-5126 | Phase 3 | Completed |
| NCT08289538 | Pexazasiran | Preclinical | Recruiting |
| NCT06306178 | Talalemzoparlimab | Phase 1 | Not yet recr... |
| NCT08215525 | RCU-2903 | NDA/BLA | Recruiting |
| NCT06718490 | IRO-8712 | Preclinical | Completed |
| NCT04931879 | Tirasacituzumab | NDA/BLA | Completed |
| NCT08802504 | Mavuvorutinib | Phase 1/2 | Not yet recr... |
| NCT03764860 | Mavuvorutinib | Phase 1/2 | Completed |
| NCT04837024 | Polasotorasib | NDA/BLA | Recruiting |
| NCT08905329 | ARX-3681 | Phase 2 | Completed |
| NCT05294221 | ARX-3681 | Phase 2 | Completed |
| NCT03055167 | DAN-IIT-673 | Preclinical | Active |
| NCT03575411 | MAY-IIT-825 | Approved | Active |
| NCT04187811 | SEO-IIT-678 | Phase 2 | Recruiting |
| NCT08274326 | CER-4594 | Phase 3 | Terminated |
| NCT03122877 | CER-4594 | Phase 3 | Active |
| NCT06709725 | Nidanesiran | Approved | Recruiting |
| NCT04447027 | Nidanesiran | Approved | Completed |
| NCT08473105 | Nidanesiran | Approved | Terminated |
| NCT03299431 | Nidanesiran | Approved | Not yet recr... |